MedTrace Logo

Itacitinib + Everolimus in Hodgkin Lymphoma

NCT03697408 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-05-30

Study results available
· View outcomes & findings →

Summary

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

Conditions

  • Classical Hodgkin Lymphoma

Interventions

DRUG

Itacitinib

A JAK 1 selective small molecule inhibitor

DRUG

Everolimus

A mammalian target of rapamycin (mTOR) inhibitor

Sponsors & Collaborators

Principal Investigators

  • Jakub Svoboda, MD · University of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2024-05-20
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697408 on ClinicalTrials.gov